Last reviewed · How we verify
Oxygen 21 %
Oxygen 21% is a hyperoxic gas mixture that increases arterial oxygen partial pressure to enhance tissue oxygenation and potentially promote healing or therapeutic benefit in hypoxic conditions.
Oxygen 21% is a hyperoxic gas mixture that increases arterial oxygen partial pressure to enhance tissue oxygenation and potentially promote healing or therapeutic benefit in hypoxic conditions. Used for Hypoxic conditions or tissue hypoxia (specific indication unclear from limited information).
At a glance
| Generic name | Oxygen 21 % |
|---|---|
| Sponsor | University of South Florida |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Critical Care or Wound Healing |
| Phase | Phase 3 |
Mechanism of action
This investigational therapy delivers a higher concentration of oxygen (21% is standard room air; this likely refers to enriched oxygen or a specific formulation) to increase dissolved oxygen in blood and improve oxygen delivery to tissues. The mechanism is based on enhancing aerobic metabolism and reducing hypoxia-related pathology in target tissues.
Approved indications
- Hypoxic conditions or tissue hypoxia (specific indication unclear from limited information)
Common side effects
- Oxygen toxicity
- Pulmonary complications
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD (NA)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma (PHASE3)
- Impact of the Early Life Virome Development on Bronchopulmonary Dysplasia in Preterm Neonates
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxygen 21 % CI brief — competitive landscape report
- Oxygen 21 % updates RSS · CI watch RSS
- University of South Florida portfolio CI